See more : Corporativo GBM, S.A.B. de C.V. (GBMO.MX) Income Statement Analysis – Financial Results
Complete financial analysis of IR-Med Inc. (IRME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IR-Med Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Rubicon Water Limited (RWL.AX) Income Statement Analysis – Financial Results
- FSE Lifestyle Services Limited (0331.HK) Income Statement Analysis – Financial Results
- MUNOTH COMMUNICATION LIMITED (MCLTD.BO) Income Statement Analysis – Financial Results
- Incross Co., Ltd. (216050.KQ) Income Statement Analysis – Financial Results
- Capital Limited (CILLF) Income Statement Analysis – Financial Results
IR-Med Inc. (IRME)
About IR-Med Inc.
IR-Med Inc., a development stage medical device company, focuses on the development of infra-red light spectroscopy combined with artificial intelligence technology platform to address diagnostic or medical needs. It is developing PressureSafe, a handheld optical monitoring device to support early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children. The company is headquartered in Rosh Pina, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 17.00K | 10.00K | 5.00K | 1.00K | 2.00K | 0.00 |
| Gross Profit | -17.00K | -10.00K | -5.00K | -1.00K | -2.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.06M | 1.89M | 1.42M | 409.00K | 61.00K | 0.00 |
| General & Administrative | 2.03M | 1.98M | 1.29M | 316.00K | 150.00K | 0.00 |
| Selling & Marketing | 822.00K | 759.00K | 888.00K | 0.00 | 147.85K | 0.00 |
| SG&A | 2.85M | 2.74M | 2.18M | 316.00K | 148.00K | 900.00 |
| Other Expenses | 0.00 | 135.00K | 74.00K | 5.00K | 0.00 | 0.00 |
| Operating Expenses | 4.89M | 4.76M | 3.68M | 730.00K | 209.00K | 900.00 |
| Cost & Expenses | 4.91M | 4.76M | 3.68M | 730.00K | 211.00K | 900.00 |
| Interest Income | 0.00 | 6.00 | 5.00 | 9.00 | 4.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 5.00K | 9.00K | 4.00K | 0.00 |
| Depreciation & Amortization | 17.00K | 10.00K | 5.00K | 1.00K | 2.00K | 0.00 |
| EBITDA | -4.89M | -4.75M | -3.67M | -729.00K | -209.00K | -900.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.91M | -4.76M | -3.68M | -730.00K | -211.00K | -900.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.00K | 28.00K | -41.00K | -22.00K | -37.00K | 0.00 |
| Income Before Tax | -4.91M | -4.73M | -3.72M | -752.00K | -248.00K | -900.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.73M | 5.00K | 9.00K | 0.00 | 0.00 |
| Net Income | -4.91M | -9.46M | -3.72M | -761.00K | -248.00K | -900.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.07 | -0.14 | -0.06 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | -0.07 | -0.14 | -0.06 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 69.40M | 67.58M | 63.11M | 30.03M | 28.91M | 112.74K |
| Weighted Avg Shares Out (Dil) | 69.40M | 67.58M | 63.11M | 30.03M | 28.91M | 112.74K |
Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
Rosh Pina, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today the start of a...
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
Rosh Pina, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that Mr. Ran Ziskind has...
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
Rosh Pina, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today it has been recognized for...
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
Rosh Pina, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- I R-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced it has received a...
IR-MED's PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel's Largest HMO
Poster presentation available here: LINK
IR-MED's PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
Rosh Pina, Israel, April 05, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, today announced its PressureSafe™ decision support...
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
Rosh Pina, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, today reported highly favorable proof of...
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from...
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
The Granted patent covers IR-MED's PressureSafe ™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually with a non-invasive device that offers more than 90% accuracy
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
Mr. Di-Cori's vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems
Source: https://incomestatements.info
Category: Stock Reports